利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

50 条记录 (耗时 0.029 秒)

    MONITORING OR FEEDBACK SYSTEMS AND METHODS
    2.
    发明申请
    MONITORING OR FEEDBACK SYSTEMS AND METHODS 有权
    监控或反馈系统和方法

    公开(公告)号：US20110181410A1

    公开(公告)日：2011-07-28

    申请号：US13016575

    申请日：2011-01-28

    申请人： Douglas A. Levinson ,  Howard Bernstein ,  Donald E. Chickering, III

    发明人： Douglas A. Levinson ,  Howard Bernstein ,  Donald E. Chickering, III

    IPC分类号： G08B21/00

    CPC分类号： G06F19/3456 ,  G06F19/00 ,  Y02A90/26

    摘要： The present invention generally relates to systems and methods for monitoring and/or providing feedback for drugs or other pharmaceuticals taken by a subject. In one aspect, the present invention is directed to devices and methods for determining a species within the skin of a subject; and producing feedback to a subject based on the determination of the species. The feedback may be, for example, visual, audible, tactile, a change in temperature, etc. In some cases, information regarding the determination of the species may be transmitted to another entity, e.g., a health care provider, a computer, a relative, etc., which may then provide feedback to the subject in some fashion. In some cases, the feedback may be directly indicative of the species, e.g., whether the species is present, the concentration of the species, whether a by-product of a reaction involving the species is present, whether a compound affected by the species is present, etc. However, the feedback may also be indirect in some embodiments. For example, the subject may be presented with an external reward, e.g., based on the determination of the species within the skin. For instance, a reward such as cash, coupons, songs, discounts, personal items, etc., may be offered based on the level of compliance of the subject. Still other aspects of the invention are generally directed to kits involving such devices (with or without the drug to be monitored), methods of promoting such systems, or the like.

    摘要翻译： 本发明一般涉及用于监测和/或提供受试者所采取的药物或其他药物的反馈的系统和方法。 一方面，本发明涉及用于确定受试者皮肤内物种的装置和方法; 并根据物种的确定向对象产生反馈。 反馈可以是例如视觉，听觉，触觉，温度变化等。在一些情况下，关于物种的确定的信息可以被传输到另一个实体，例如医疗保健提供者，计算机， 相对等，其然后可以以某种方式向受试者提供反馈。 在一些情况下，反馈可以直接指示物种，例如物种是否存在，物种的浓度，是否存在涉及物种的反应的副产物，受物种影响的化合物是否为 存在等。然而，在一些实施例中，反馈也可以是间接的。 例如，受试者可以例如基于皮肤内物种的确定来呈现外部奖励。 例如，可以基于主体的合规级别来提供诸如现金，优惠券，歌曲，折扣，个人物品等的奖励。 本发明的其它方面通常涉及涉及这种装置的试剂盒（有或没有待监测的药物），促进这种系统的方法等。

    Porous paclitaxel matrices and methods of manufacture thereof
    5.
    再颁专利
    Porous paclitaxel matrices and methods of manufacture thereof 有权
    多孔紫杉醇基质及其制备方法

    公开(公告)号：USRE40493E1

    公开(公告)日：2008-09-09

    申请号：US11213257

    申请日：2005-08-26

    申请人： Julie A. Straub ,  Howard Bernstein ,  Donald E. Chickering, III ,  Sarwat Khattak ,  Greg Randall

    发明人： Julie A. Straub ,  Howard Bernstein ,  Donald E. Chickering, III ,  Sarwat Khattak ,  Greg Randall

    IPC分类号： A61K9/14 ,  A61K9/70 ,  A61F2/00

    CPC分类号： A61K9/1623 ,  A61K9/1611 ,  A61K9/1635 ,  A61K9/1694 ,  Y10S977/906

    摘要： Paclitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The paclitaxel matrices preferably are made using a process that includes (i) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combining at least one pore forming agent with the paclitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of paclitaxel. The pore forming agent can be either a volatile liquid that is immiscible with the paclitaxel solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. In a preferred embodiment, microparticles of the porous paclitaxel matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

    摘要翻译： 紫杉醇以多孔基质形式提供，其允许药物在没有Cremophor的情况下配制并作为大剂量给药。 紫杉醇基质优选使用包括（i）将紫杉醇溶解在挥发性溶剂中以形成紫杉醇溶液的方法制备，（ii）将至少一种成孔剂与紫杉醇溶液组合以形成乳液，悬浮液或第二溶液 ，和（iii）从乳液，悬浮液或第二溶液中除去挥发性溶剂和成孔剂以产生紫杉醇的多孔基质。 成孔剂可以是与紫杉醇溶剂或挥发性固体化合物，优选挥发性盐不混溶的挥发性液体。 在优选的实施方案中，使用喷雾干燥来除去溶剂和成孔剂。 在优选的实施方案中，多孔紫杉醇基质的微粒用水性介质重新配制，并肠胃外给药，或使用标准技术加工成用于口服给药的片剂或胶囊。

    Porous drug matrices and methods of manufacture thereof
    8.
    发明授权
    Porous drug matrices and methods of manufacture thereof 有权
    多孔药物基质及其制造方法

    公开(公告)号：US08821938B2

    公开(公告)日：2014-09-02

    申请号：US13022776

    申请日：2011-02-08

    申请人： Julie Straub ,  David Altreuter ,  Howard Bernstein ,  Donald E. Chickering, III ,  Sarwat Khattak ,  Greg Randall

    发明人： Julie Straub ,  David Altreuter ,  Howard Bernstein ,  Donald E. Chickering, III ,  Sarwat Khattak ,  Greg Randall

    IPC分类号： A61K9/14 ,  A61K9/00 ,  A61K31/335 ,  A01N43/02

    CPC分类号： A61K9/1635 ,  A61K9/1611 ,  A61K9/1623 ,  A61K9/1688 ,  A61K9/1694

    摘要： Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

    摘要翻译： 药物，特别是低含水溶性药物以多孔基质形式提供，优选微粒，其增强药物在水性介质中的溶解。 药物基质优选使用以下方法制备，所述方法包括（i）将挥发性溶剂中的药物（优选为低溶解度的药物）溶解以形成药物溶液，（ii）将至少一种成孔剂与药物溶液 以形成稳定药物并抑制结晶的乳液，悬浮液或第二溶液和亲水或疏水赋形剂，和（iii）从乳液，悬浮液或第二溶液中除去挥发性溶剂和成孔剂以产生多孔基质 药物。 可以选择疏水性或亲水性赋形剂，以通过抑制晶体生长来稳定药物的结晶形式，或者通过防止结晶来稳定药物的无定形形式。 成孔剂可以是与药物溶剂或挥发性固体化合物，优选挥发性盐不混溶的挥发性液体。 在优选的实施方案中，使用喷雾干燥来除去溶剂和成孔剂。 与药物的无孔基质形式相比，得到的多孔基质在给予患者后具有更快的溶解速率。 在优选的实施方案中，多孔药物基质的微粒用水性介质重新配制，并肠胃外给药，或使用标准技术加工成用于口服给药的片剂或胶囊。